Ana Janic

Dr. Ana Janic

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2010 in Science
Verified
Journal Article
Closed access
PDF file
AJAna Janic
Ana Janic
LMLeire Mendizabal
Leire Mendizabal
SLSalud Llamazares
Salud Llamazares
DRDavid Rossell
David Rossell
Cayetano GonzalezCayetano Gonzalez
Cayetano Gonzalez
Curing Insect Brain Tumors: Mammalian tumors often show ectopic expression of genes that normally function only in the germ line. The possible contribution of cancer germline (CG) genes to malignancy is unknown. Janic et al. (p. 1824 ; see the Perspective by Wu and Ruvkun ) found that CG genes are also expressed in Drosophila brain tumors caused by mutants in the gene lethal (3) malignant brain tumor . Moreover, inactivation of some of these genes suppressed fly tumor growth. Because some Drosophila CG genes are orthologs of human CG genes, it is possible that inactivation of germline genes may show human tumor suppressor activity.

1 May 2013 in Cell Reports
Verified
Journal Article
Open access
LVLiz J. Valente
Liz J. Valente
DGDaniel H.D. Gray
Daniel H.D. Gray
EMEwa M. Michalak
Ewa M. Michalak
JHJosefina Piñón Hofbauer
Josefina Piñón Hofbauer
AEAlex Egle
Alex Egle
ASAndreas Strasser
Andreas Strasser
Activation of apoptosis through transcriptional induction of Puma and Noxa has long been considered to constitute the critical (if not sole) process by which p53 suppresses tumor development, although G1/S boundary cell-cycle arrest via induction of the CDK inhibitor p21 has also been thought to contribute. Recent analyses of mice bearing mutations that impair p53-mediated induction of select target genes have indicated that activation of apoptosis and G1/S cell-cycle arrest may, in fact, be dispensable for p53-mediated tumor suppression. However, the expression of Puma, Noxa, and p21 was not abrogated in these mutants, only reduced; therefore, the possibility that the reduced levels of these critical effectors of p53-mediated apoptosis and G1/S-cell-cycle arrest sufficed to prevent tumorigenesis could not be excluded. To resolve this important issue, we have generated mice deficient for p21, Puma, and Noxa (p21-/-puma-/-noxa-/- mice). Cells from these mice were deficient in their ability to undergo p53-mediated apoptosis, G1/S cell-cycle arrest, and senescence. Nonetheless, these animals remained tumor free until at least 500 days, in contrast to p53-deficient mice, which had all succumbed to lymphoma or sarcoma by 250 days. Interestingly, DNA lesions induced by γ-irradiation persisted longer in p53-deficient cells compared to wild-type or p21-/-puma-/-noxa-/- cells, and the former failed to transcriptionally activate several p53 target genes implicated in DNA repair. These results demonstrate beyond a doubt that the induction of apoptosis, cell-cycle arrest, and possibly senescence is dispensable for p53-mediated suppression of spontaneous tumor development and indicate that coordination of genomic stability and possibly other processes, such as metabolic adaptation, may instead be critical.

11 June 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AJAna Janic
Ana Janic
LVLiz J. Valente
Liz J. Valente
MWMatthew J. Wakefield
Matthew J. Wakefield
LSLeon Di Stefano
Leon Di Stefano
LMLiz Milla
Liz Milla
MHMarco Herold
Marco Herold

13 September 2009 in Nature Genetics
Verified
Journal Article
Closed access
AMAnne-Marie Martinez
Anne-Marie Martinez
BSBernd Schuettengruber
Bernd Schuettengruber
SSSamy Sakr
Samy Sakr
AJAna Janic
Ana Janic
Cayetano GonzalezCayetano Gonzalez
Cayetano Gonzalez
Giacomo CavalliGiacomo Cavalli
Giacomo Cavalli

20 February 2024 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
AJAna Janic
Ana Janic
EAEtna Abad
Etna Abad
IAIvano Amelio
Ivano Amelio
Genomic instability, a hallmark of cancer, is a direct consequence of the inactivation of the tumor suppressor protein p53. Genetically modified mouse models and human tumor samples have revealed that p53 loss results in extensive chromosomal abnormalities, from copy number alterations to structural rearrangements. In this perspective article we explore the multifaceted relationship between p53, genomic stability, and epigenetic control, highlighting its significance in cancer biology. p53 emerges as a critical regulator of DNA repair mechanisms, influencing key components of repair pathways and directly participating in DNA repair processes. p53 role in genomic integrity however extends beyond its canonical functions. p53 influences also epigenetic landscape, where it modulates DNA methylation and histone modifications. This epigenetic control impacts the expression of genes involved in tumor suppression and oncogenesis. Notably, p53 ability to ensure cellular response to DNA demethylation contributes to the maintenance of genomic stability by preventing unscheduled transcription of repetitive non-coding genomic regions. This latter indicates a causative relationship between the control of epigenetic stability and the maintenance of genomic integrity in p53-mediated tumor suppression. Understanding these mechanisms offers promising avenues for innovative therapeutic strategies targeting epigenetic dysregulation in cancer and emphasizes the need for further research to unravel the complexities of this relationship. Ultimately, these insights hold the potential to transform cancer treatment and prevention strategies.

26 October 2018 in Genes & Development
Verified
Journal Article
Open access
PDF file
BABrandon J. Aubrey
Brandon J. Aubrey
AJAna Janic
Ana Janic
YCYunshun Chen
Yunshun Chen
CCCatherine Chang
Catherine Chang
ELElizabeth C. Lieschke
Elizabeth C. Lieschke
Gemma KellyGemma Kelly
Gemma Kelly
Mutations in Trp53, prevalent in human cancer, are reported to drive tumorigenesis through dominant-negative effects (DNEs) over wild-type TRP53 function as well as neomorphic gain-of-function (GOF) activity. We show that five TRP53 mutants do not accelerate lymphomagenesis on a TRP53-deficient background but strongly synergize with c-MYC overexpression in a manner that distinguishes the hot spot Trp53 mutations. RNA sequencing revealed that the mutant TRP53 DNE does not globally repress wild-type TRP53 function but disproportionately impacts a subset of wild-type TRP53 target genes. Accordingly, TRP53 mutant proteins impair pathways for DNA repair, proliferation, and metabolism in premalignant cells. This reveals that, in our studies of lymphomagenesis, mutant TRP53 drives tumorigenesis primarily through the DNE, which modulates wild-type TRP53 function in a manner advantageous for neoplastic transformation.